$HRGN
Harvard Apparatus Regenerative Technology Inc

2018 Q1 Form 10-Q Financial Statement

#000114420418027643 Filed on May 11, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $928.0K $979.0K
YoY Change -5.21% -10.51%
% of Gross Profit
Research & Development $552.0K $2.069M
YoY Change -73.32% 50.15%
% of Gross Profit
Depreciation & Amortization $63.00K $121.0K
YoY Change -47.93% 9.01%
% of Gross Profit
Operating Expenses $1.480M $3.048M
YoY Change -51.44% 23.3%
Operating Profit -$1.480M -$3.048M
YoY Change -51.44% 23.3%
Interest Expense -$120.0K -$790.0K
YoY Change -84.81%
% of Operating Profit
Other Income/Expense, Net -$65.00K -$793.0K
YoY Change -91.8%
Pretax Income -$1.545M -$3.841M
YoY Change -59.78% 55.38%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.545M -$3.841M
YoY Change -59.78% 55.38%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$563.6K -$2.824M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.820M $6.580M
YoY Change -57.14% 35.67%
Cash & Equivalents $2.819M $6.582M
Short-Term Investments
Other Short-Term Assets $36.00K $36.00K
YoY Change 0.0% -92.65%
Inventory
Prepaid Expenses $249.0K
Receivables $60.00K $37.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $3.270M $6.900M
YoY Change -52.61% 27.07%
LONG-TERM ASSETS
Property, Plant & Equipment $590.0K $1.050M
YoY Change -43.81% -7.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $590.0K $1.053M
YoY Change -43.97% -7.22%
TOTAL ASSETS
Total Short-Term Assets $3.270M $6.900M
Total Long-Term Assets $590.0K $1.053M
Total Assets $3.860M $7.953M
YoY Change -51.46% 21.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $240.0K $713.0K
YoY Change -66.34% 170.08%
Accrued Expenses $430.0K $920.0K
YoY Change -53.26% 666.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $809.0K $6.430M
YoY Change -87.42% 1557.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $809.0K $6.430M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $809.0K $6.430M
YoY Change -87.42% 1557.22%
SHAREHOLDERS EQUITY
Retained Earnings -$49.78M
YoY Change
Common Stock $29.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.048M $1.523M
YoY Change
Total Liabilities & Shareholders Equity $3.857M $7.953M
YoY Change -51.5% 21.14%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$1.545M -$3.841M
YoY Change -59.78% 55.38%
Depreciation, Depletion And Amortization $63.00K $121.0K
YoY Change -47.93% 9.01%
Cash From Operating Activities -$2.060M -$3.055M
YoY Change -32.57% 23.19%
INVESTING ACTIVITIES
Capital Expenditures $3.000K $105.0K
YoY Change -97.14% -17.97%
Acquisitions
YoY Change
Other Investing Activities $50.00K
YoY Change
Cash From Investing Activities $46.00K -$105.0K
YoY Change -143.81% -19.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $100.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 795.0K $6.801M
YoY Change -88.31%
NET CHANGE
Cash From Operating Activities -2.060M -$3.055M
Cash From Investing Activities 46.00K -$105.0K
Cash From Financing Activities 795.0K $6.801M
Net Change In Cash -1.219M $3.641M
YoY Change -133.48% -239.5%
FREE CASH FLOW
Cash From Operating Activities -$2.060M -$3.055M
Capital Expenditures $3.000K $105.0K
Free Cash Flow -$2.063M -$3.160M
YoY Change -34.72% 21.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 bstg Product Distribution Agreement Term
ProductDistributionAgreementTerm
P10Y
CY2018Q1 us-gaap Cash
Cash
2819000 USD
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
809000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1622000 USD
CY2018Q1 us-gaap Liabilities
Liabilities
809000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
1622000 USD
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
29000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
25000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49779000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48234000 USD
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
51323000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
50157000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
3048000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
3423000 USD
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3857000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5045000 USD
CY2017Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
383000 USD
CY2018Q1 us-gaap Other Assets Current
OtherAssetsCurrent
36000 USD
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
16000 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
289000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-249000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
47000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-293000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2060000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6801000 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
86000 USD
CY2018Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0 USD
CY2017Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
300000 USD
CY2018Q1 us-gaap Revenues
Revenues
0 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
552000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2069000 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
1480000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
3048000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1480000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3048000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1545000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-3841000 USD
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2751000 shares
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1359000 shares
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.83
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1545000 USD
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
928000 USD
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
124000 USD
CY2018Q1 bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
124000 USD
CY2017Q1 bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
793000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5000 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
68000 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-42000 USD
CY2018Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1000 USD
CY2017Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-176000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-698000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3055000 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
105000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
46000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-105000 USD
CY2018Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1095000 USD
CY2017Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6801000 USD
CY2018Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
14000 USD
CY2017Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
795000 USD
CY2017Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
0 USD
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1219000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3641000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4038000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2941000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2819000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6582000 USD
CY2018Q1 bstg Fair Value Of Liability Warrants Issued In Connection With Issuance Of Common Stock
FairValueOfLiabilityWarrantsIssuedInConnectionWithIssuanceOfCommonStock
0 USD
CY2017Q1 bstg Fair Value Of Liability Warrants Issued In Connection With Issuance Of Common Stock
FairValueOfLiabilityWarrantsIssuedInConnectionWithIssuanceOfCommonStock
3787000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75000 USD
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1044000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
51000 USD
CY2018Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
140000 USD
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
16000 USD
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75000 USD
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
191000 USD
CY2018Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
300000 USD
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1414143 shares
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5897350 shares
CY2017Q4 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
20 pure
CY2017Q4 us-gaap Restructuring Costs
RestructuringCosts
99000 USD
CY2017Q4 us-gaap Restructuring And Related Cost Description
RestructuringAndRelatedCostDescription
In addition, officers of the Company agreed to a temporary reduction in their salaries by 50% effective November 2017.
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2859419 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2507304 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2507304 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2859419 shares
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-793000 USD
CY2017 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.850 pure
CY2018Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2018Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0248 pure
CY2017 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0209 pure
CY2018Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.9473 pure
CY2017 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.00
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.00
CY2018Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
92212 shares
CY2017Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
92212 shares
CY2018Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P3Y10M24D
CY2017 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y1M6D
CY2018Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
59000 USD
CY2018Q1 bstg Grant Income
GrantIncome
59000 USD
CY2017Q1 bstg Grant Income
GrantIncome
0 USD
CY2018Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
59000 USD
CY2017Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
0 USD
CY2018Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
49000 USD
CY2017Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2018Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
300000 USD
CY2017Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
CY2018Q1 bstg Maximum Research And Development Expenses Reimbursement
MaximumResearchAndDevelopmentExpensesReimbursement
225000 USD
CY2018Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
The SBIR grant has the potential to provide a total award up to $1.7 million. If Phase I is successful, and funding is available, a Phase II award of up to approximately $1.5 million would support pre-clinical testing of pediatric Cellspan Esophageal Implants planned to begin later in 2018. The Phase II Funds, if awarded, would be spent over an estimated two years.
CY2018Q1 us-gaap Share Price
SharePrice
3.10
CY2017Q4 us-gaap Share Price
SharePrice
0.87
CY2017Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2100000 USD
CY2017Q4 bstg Warrant Expiration Date
WarrantExpirationDate
2022-12-31
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000 USD
CY2018Q1 bstg Warrant Expiration Date
WarrantExpirationDate
2023-01-31
CY2018Q1 bstg Percentage Of Salary Of Officers On Contracted Rate
PercentageOfSalaryOfOfficersOnContractedRate
0.8 pure
CY2018Q1 us-gaap Payments For Postemployment Benefits
PaymentsForPostemploymentBenefits
99000 USD
CY2018Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
124000 USD

Files In Submission

Name View Source Status
0001144204-18-027643-index-headers.html Edgar Link pending
0001144204-18-027643-index.html Edgar Link pending
0001144204-18-027643.txt Edgar Link pending
0001144204-18-027643-xbrl.zip Edgar Link pending
bstg-20180331.xml Edgar Link completed
bstg-20180331.xsd Edgar Link pending
bstg-20180331_cal.xml Edgar Link unprocessable
bstg-20180331_def.xml Edgar Link unprocessable
bstg-20180331_lab.xml Edgar Link unprocessable
bstg-20180331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv493805_10q.htm Edgar Link pending
tv493805_ex31-1.htm Edgar Link pending
tv493805_ex31-2.htm Edgar Link pending
tv493805_ex32-1.htm Edgar Link pending
tv493805_ex32-2.htm Edgar Link pending